Proteolysis resistant active VEGF

Details Proteolysis resistant active VEGF Proteolysis resistant active VEGF

2003-03-06

2009-02-17

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C530S399000, C435S069100, C435S320100, C536S023500

Reexamination Certificate

active

07491696

ABSTRACT:
The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.

REFERENCES:
patent: 5219739 (1993-06-01), Tischer et al.
patent: 6057428 (2000-05-01), Keyt et al.
Powers, J.C. et al, “Proteases-structures, mechanism and inhibitors”, NCBI abstract of Agents Actions Suppl., 42: 3-18 (1993) (Abstract).
Robinson, C. J. et al, “The splice variants of vascular endothelial growth factor (VEGF) and their receptors”, Journal of cell Science, England, Vo. 114, No. Pt 5 (Mar. 2001).
Scharffetter-Kochanek, K. et al, “Chronische Wunden und Wachstumsfaktoren Chronic wounds and growth factors”, Zeitschrift für Hautkankheiten, H&G, 11 (74): 664-672 (1999).
Soker, S. et al, “Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor”, Cell, vol. 92: 735-745 (Mar. 20, 1998).
Wu, X.C. et al, “Engineering of plasmin-resistant forms of streptokinase and their production inBacillus subtilis: streptokinase with longer functional half-life”, Appl Environ Microbiol., 64(3):824-9 (Mar. 1998).
Powers, J.C. et al, “Proteases-structures, mechanism and inhibitors”, inProteases, Protease Inhibitors and Protease Derived Peptides, Agents Actions Suppl., 42: 3-18 (Publ. Birkhaeuser, 1993).
Frank, S. et al, “Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes Implications for Normal and Impaired Wound Healing”, JBC Online, vol. 270, No. 21: 12607-12613 (May 16, 1995).
Fukumura, D. et al, “Tumor Induction of VEGF Promoter Activity in Stromal Cells”, Cell, vol. 94: 715-725 (Sep. 18, 1998).
Gospodarowicz, D. et al, “Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells”, Proc. Natl. Acad. Sci. USA, vol. 86: 7311-7315 (Oct. 1989).
Keck, P. et al, “Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF”, Science, vol. 246: 1309-1312 (Dec. 8, 1989).
Keyt, B. et al, “The Carboxyl-terminal Domain (111-165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency”, The Journal of Biological Chemistry, vol. 271, No. 13: 7788-7795 (Mar. 29, 1996).
Lauer, G. et al, “Expression and Proteolysis of Vascular Endothelial Growth Factor is Increased in Chronic Wounds”, The Journal of Investigative Dermatology, vol. 115, No. 1: 12-18 (Jul. 2000).
Lauer, G. et al, “Expression of the soluble variant of the vascular endothelial growth factor receptor Flt-1 in chronic wounds”, Wound Repair and Regeneration, Vo. 8, No. 5 (Sep. 2000).
Lauer, G. et al, “Generation of a novel proteolysis resistant vascular endothelial growth factor 165 variant by a site-directed mutation at the plasmin sensitive cleavage site”, FEBS Lett., 531(2):309-13 (Nov. 6, 2002).
Lauer, G. et al, “VEGF Expression chronic non-healing wounds”, Archives of Dermatological Research, vol. 293, No. 1-2, P145, p. 79 (Feb. 2001).
Lawrence, W. et al, “Growth Factors in Wound Healing”, Clinics in Dermatology, 12: 157-169 (1994).
Market, Y. et al, “Increased proteolytic resistance of ribonuclease A by protein engineering”, Protein Engineering, England, vol. 14, No. 10 (Oct. 2001).
Mohanraj, D. et al, “Expression of Biologically Active Human Vascular Endothelial Growth Factor in Yeast”, Growth Factors, vol. 12: 17-27 (1995).
Nissen, N. et al, “Vascular Endothelial Growth Factor Mediates Angiogenic Activity during the Proliferative Phase of Wound Healing”, American Journal of Pathology, vol. 152, No. 6: 1445-1452 (Jun. 1998).

Affiliated with

Also associated with

Rating

Proteolysis resistant active VEGF does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Proteolysis resistant active VEGF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteolysis resistant active VEGF will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4088613